Altogether, therapeutic targeting of the LOX family members, especially LOX and LOXL2, by promoting the tumor suppressive function of LOX and/or inhibiting the activity or expression of these enzymes, may offer viable ways to combat melanoma and other cancers. The gene discussed is LOXL2; the disease is neoplasm.